Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: Bladder Cancer
April 23, 2021
Bladder cancer is the fifth most common cancer in the US and Europe, and the ninth most common cancer worldwide. Datamonitor Healthcare estimates that in 2018, there were 546,400 incident cases of bladder cancer globally, and expects that number to increase to 605,300 incident cases by 2027.
PD-1/PD-L1 inhibitors remain the dominant class in the bladder cancer market in terms of patient share, and label expansion into earlier disease stages such as non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) will further grow the overall bladder cancer market.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Bladder Cancer|